Risk factors for ulcerative colitis: A population-based, case–control study in Spain

Sicilia, Beatriz; Arribas, Francisco Javier Rubio; Nerín, Juan Pedro Barret; Miguel, C. López; Vicente, Raquel; Gomollón, Fernando

doi:10.1016/j.crohns.2008.01.003

Cited by 13 publications

(8 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The condition is more and more common worldwide, especially in highly developed societies, and its prevalence varies by geographic region, ranging from 4.9 to 505 per 100 000 in Europe, 4.9 to 168.3 per 100 000 in Asia and the Middle East, and 37.5 to 248.6 per 100 000 in North America [ 3 , 4 ]. The fact that the highest incidence and prevalence of UC are in the populations of Europe and North America is considered to be linked to genetic factors, environment, and lifestyle, particularly to a diet high in fat and sugar, alcohol, medication use, stress, and high socioeconomic status [ 1 , 3 , 5 – 12 ]. The goal of therapy in UC is to induce and maintain remission, improve quality of life, and prevent colectomy [ 13 – 15 ].…”

Section: Introductionmentioning

confidence: 99%

An indirect comparison of infliximab versus adalimumab or golimumab for active ulcerative colitis

Kawalec¹,

Pilc

2016

aoms

View full text Add to dashboard Cite

IntroductionThe aim of the study was to compare adalimumab or golimumab with infliximab in patients with moderately-to-severely active ulcerative colitis (UC).Material and methodsThis paper was prepared according to the PRISMA guidelines. The systematic literature search was performed in PubMed, Embase, and Cochrane Library. No direct head-to-head comparisons for infliximab vs. adalimumab or golimumab were available so an indirect comparison according to the Bucher method was performed after a homogeneity evaluation of the included studies.ResultsSix RCTs were included in the systematic review. An indirect comparison was performed, which revealed that infliximab was more effective in inducing clinical response compared with both doses of adalimumab (160/80 mg or 80/40 mg; p < 0.05), and, in clinical remission, infliximab was more effective than adalimumab (only for a dosage regime of 80/40 mg; p < 0.05). No statistically significant differences in clinical response and clinical remission were observed between infliximab and golimumab in the induction phase. A significant (p < 0.05) advantage only of infliximab compared with adalimumab at doses of 80/40 mg and 80/160 mg was seen in terms of clinical response in the maintenance phase (up to 52–54 weeks). The indirect comparison revealed that serious adverse events were significantly more frequent among patients treated with a maintenance dose of 100 mg of golimumab compared with those treated with infliximab (p < 0.05).ConclusionsNo significant differences in efficacy in the maintenance phase between infliximab and golimumab or adalimumab were revealed. Infliximab proved to be more effective than adalimumab but of similar efficacy to that of golimumab in the induction phase.

show abstract

Section: Introductionmentioning

confidence: 99%

An indirect comparison of infliximab versus adalimumab or golimumab for active ulcerative colitis

Kawalec¹,

Pilc

2016

aoms

View full text Add to dashboard Cite

show abstract

“…However, previous reports had suggested that smokers, particularly those who smoked before the HS, had a less severe form of HS than those who had never smoked . In addition, current smoking is a protective factor in other inflammatory diseases such as ulcerative colitis . Larger studies are needed to determine better the protective effect of tobacco use in patients with HS.…”

Section: Initial Characteristics Of Patients With Hidradenitis Suppurmentioning

confidence: 99%

Antitumour necrosis factor-α therapy for hidradenitis suppurativa: results from a national cohort study between 2000 and 2013

Sbidian

Hotz

Sénéschal

et al. 2016

British Journal of Dermatology

View full text Add to dashboard Cite

International audienceHidradenitis suppurativa (HS) is a frequent chronic inflammatory skin disease typically characterized by recurrent painful, deep inflammatory nodules of the axillary, breast, groin and gluteal areas. European recommendations are mainly based on expert opinion. Drug treatments are heterogenous (e.g., antibiotics, corticosteroids, retinoids) and lack consensus among expert centres. The most severe disease forms or those failing to respond to conventional drugs may be associated with worsened functional prognosis. Anti-tumor necrosis factor α (anti-TNFα) drugs have been prescribed in these cases. The results of randomized controlled trials (RCTs) are discordant. Three RCTs concluded to the efficacy of adalimumab (ADA), and two others did not detect any difference between infliximab (IFX) or etanercept (ETA) and placebo. Finally, data from the literature and reported experiences do not conclude on the efficacy of anti-TNFα drugs for HS. This article is protected by copyright. All rights reserve

show abstract

“… 3 4 5 6 Furthermore, some recent clinical studies have found no association between OCP and the development of IBD. 2 20 21 22 23 24 25 26 These studies were, however, limited by small female sample sizes 20 23 24 25 26 or inclusion of males in the total analyses, 2 21 25 which may result in underpowering and inability to detect an association. Other studies did not evaluate modern OCP formulations.…”

Section: Introductionmentioning

confidence: 99%

The association between new generation oral contraceptive pill and the development of inflammatory bowel diseases

Sanagapalli

Kariyawasam

et al. 2018

Intest Res

View full text Add to dashboard Cite

Background/AimsTo examine the association between use of oral contraceptive pills (OCPs) and the risk of developing inflammatory bowel diseases (IBD), in a modern cohort.MethodsA prospective nested case-control study across sites in the Asia-Pacific region was conducted; involving female IBD cases and asymptomatic controls. Subjects completed a questionnaire addressing questions related to OCP use. Primary outcome was the risk of development of IBD of those exposed to OCP versus non-exposure. Secondary outcomes were development of Crohn's disease (CD) versus ulcerative colitis (UC), and whether age of first use of OCP use may be associated with risk of IBD.ResultsThree hundred and forty-eight female IBD cases (41% CD, median age: 43 years) and 590 female age-matched controls were recruited. No significant association was found between OCP use and the risk of IBD (odds ratio [OR], 1.65; 95% confidence interval, 0.77–3.13; P=0.22), CD (OR, 1.55) or UC (OR, 1.01). The lack of association persisted when results were adjusted for age and smoking. IBD cases commenced OCP use at a younger age than controls (18 years vs. 20 years, P=0.049).ConclusionsIn this large cohort of subjects from the Asia-Pacific region, we found a modest but not significantly increased risk of developing IBD amongst OCP users.

show abstract

Risk factors for ulcerative colitis: A population-based, case–control study in Spain

Abstract: Ex-smoking and previous family history of inflammatory bowel disease appeared as risk factors for developing ulcerative colitis while current smoking behaved as a protective factor in this population.

Cited by 13 publications

References 18 publications

An indirect comparison of infliximab versus adalimumab or golimumab for active ulcerative colitis

An indirect comparison of infliximab versus adalimumab or golimumab for active ulcerative colitis

Antitumour necrosis factor-α therapy for hidradenitis suppurativa: results from a national cohort study between 2000 and 2013

The association between new generation oral contraceptive pill and the development of inflammatory bowel diseases

Contact Info

Product

Resources

About